SEARCH

SEARCH BY CITATION

References

  • 1
    Tytgat GNJ. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol 2001; 13 (Suppl. 1): S2933.
  • 2
    Physician's Desk Reference. Monographies of Proton Pump Inhibitors. Thomson Healthcare, Montvale, NJ, USA 2005.
  • 3
    Chiverton SG, Howden CW, Burget DW, Hunt RH. Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration. Aliment Pharmacol Ther 1992; 6: 10311.
  • 4
    Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12: 123540.
  • 5
    Shimatani T, Inoue M, Kuriowa T, Horikawa Y. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 2004; 19: 11322.
  • 6
    Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 2000; 14: 70914.
  • 7
    Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 2004; 20: 399406.
  • 8
    Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 7637.
    Direct Link:
  • 9
    Kuo B, Catell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996; 91: 15328.
  • 10
    Gillen D, Wirz AA, McColl KE. Esomeprazole 40 mg bd Produces Profound 24 h Acid Suppression with Minimal Acid Breakthrough. Proceedings of the AGA Annual Conference, Digestive Disease Week 2003, Orlando Florida, 17–22 May. Gastroenterology (Suppl.), April 2003 (Abstract S1610).
  • 11
    Hammer J, Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther 2004; 19: 110510.
  • 12
    Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 12314.
  • 13
    Uchiyama K, Wakatsuki D, Kakinoki B, Takeuchi Y, Araki T, Morinaka Y. The long-lasting effect of TU-199, a novel H+, K+-ATPase inhibitor, on gastric acid secretion in dogs. J Pharm Pharmacol 1999; 51: 45764.
  • 14
    Uchiyama K, Wakatsuki D, Kakinoki B, Takeuchi Y, Araki T, Morinaka Y. Effects of TU-199, a novel H+, K+-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Methods Find Exp Clin Pharmacol 1999; 24: 11422.
  • 15
    Kakinoki B, Ono C, Yamazaki N, Chikamatsu N, Uchiyama K, Morinaka Y. General pharmacological properties of the new proton pump inhibitor (±)-5-methoxy-2-[[(4-methoxy-3,5-dimethylpyrid-2-yl)methyl]sylfinyl]-1H-imidazol[4,5-b]pyridine. Methods Find Exp Clin Pharmacol 1999; 21: 17987.
  • 16
    Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc 2004; 126: 780011.
  • 17
    Domagala F, Ficheux H. Pharmacokinetics of Tenatoprazole, a Novel Proton Pump Inhibitor, in Healthy Male Caucasian Volunteers. Proceedings of the AGA Annual Conference, Digestive Disease Week 2003, Orlando Florida, 17–22 May. Gastroenterology (Suppl.), April 2003 (Abstract #102823).
  • 18
    Galmiche JP, Bruley des Varannes S, Ducrotté P, et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life. Effects on intragastric pH and comparison with esomeprazole in Caucasian healthy volunteers. Aliment Pharmacol Ther 2004; 19: 65562.
  • 19
    Galmiche JP, Sacher-Huvelin S, Bruley des Varannes S, et al. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. Aliment Pharmacol Ther 2005; 21: 57582.
  • 20
    Hunt RH, Amstrong D, James C, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 2005; 100: 194956.
    Direct Link:
  • 21
    Mock T, Yatscoff R, Foster R, et al. Clinical validation of the HellKit(TM): a 13C urea breath test used for the diagnosis of Helicobacter infection. Clin Biochem 1999; 32: 5963.
  • 22
    Frazzoni M, De Micheli E, Savarino V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. Aliment Pharmacol Ther 2003; 18: 10918.
  • 23
    Ours TM, Fackler K, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98: 54550.
    Direct Link:
  • 24
    Nzeako UC, Murray JA. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther 2002; 16: 130916.
  • 25
    Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 32735.
  • 26
    Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. NEJM 1999; 340: 82531.
  • 27
    Pehlivanov ND, Olyaee M, Sarosiek I, McCallum RW. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther 2003; 18: 88390.
  • 28
    Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996; 38: 64954.